Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Genetics Institute Inc.
Stuart Weisbrod of Merrill Lynch raised his long-term rating to "buy" from "above average"
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury